StemCell Therapy

The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.

According to a new market intelligence report by BIS Research, titled Global Carrier Screening Market- Analysis and Forecast, 2019-2029, the global carrier screening market was valued at $846.9 million in 2018, and is estimated to grow over $2.93 billion by 2029. The global carrier screening market is expected to grow at a compound annual growth rate (CAGR) of 11.59% during the forecast period from 2019 to 2029.

The development of the market is aided by the impressive growth in the field of non-invasive prenatal testing (NIPT), genetic testing, and precision medicine.

Browse 16 Market Data Tables and 142 Figures spread through 201 Pages and in-depth TOC on "Global Carrier Screening Market"

Genetic diseases are the leading cause of the infant death, accounting for approximately 20% of annual infant mortality in the U.S. Advancements in the technological platforms in the genomic medicine have made possible low cost, pan-ethnic expanded carrier screening, enabling obstetric care providers to offer screening for over 100 recessive genetic disorders.

However, the rapid integration of use of genomic medicine into routine obstetric practices has eventually raised concerns about the implementation of carrier testing.

Technological and other advancements over the past decade have led to the discovery of thousands of genes that are associated with autosomal and X-linked recessive Mendelian disorders. Recent improvements in assessing the individual variants in the human genome, generally offer the possibility of testing populations for all known severe recessive genetic disorders.

For decades, general population carrier screening was based on the clinical validity and the utility to direct services based on ethnicity, social factors or race that may lead to particular conditions being more common in a particular group. With advancement in genetic knowledge and technologies, carrier screening for disorders such as cystic fibrosis has now become a part of primary care.

BIS Research Report: bisresearch.com/industrarket.html

With genetic screening, arises several important legal issues such as insurance and employment discrimination, confidentiality, and informed consent for both testing and treatment. Approximately, seven states have laws that penalize providers for violating a patients privacy regarding the genetic information of patients and 27 states require consent for disclosure of genetic information to the third parties.

According to Wahid Khan, Principal Analyst at BIS Research North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market value. However, Asia-Pacific is expected to grow at an impressive CAGR of 15.97% during the forecast period from 2019 to 2029.

Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of total global market value.

Research Highlights:

Report: bisresearch.com/requeste=download

This market intelligence report provides a multidimensional view of the global carrier screening market in terms of market size and growth potential. This research report aims at answering various aspects of the global carrier screening market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches, regulatory clearance, and certifications, partnerships, collaborations, business expansions as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales and manufacturers and trend analysis by segment and demand analysis by geographical region.

This report is a meticulous compilation of research on more than 30 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The report also profiles 15 key companies, namely, Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., Invitae Corporation, Eurofins Scientific, GenMark Diagnostics, 23and Me, Inc., Sema4, BGI, Centogene AG, Pathway Genomics, and Gene By Gene.

Key Questions Answered in the Report:

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more here:
Global Carrier Screening Market to reach $2.93 billion by 2029 according to a new research report - WhaTech - WhaTech

This entry was posted on November 14, 2019 at 4:51 pm and is filed under Legal Issues Genetic Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |